FindTrial
Sign In

Regional difference in dopamine D2 receptor occupancy by aripiprazole in humans: a positron emission tomography study.

Regional difference in dopamine D2 receptor occupancy by aripiprazole in humans: a positron emission tomography study. - Regional difference in dopamine D2 receptor occupancy by aripiprazole in humans: a positron emission tomography study.

Status
Active, not recruiting
Phases
Unknown
Study type
Interventional
Source
JPRN
Registry ID
JPRN-UMIN000004357
Enrollment
15
Registered
2010-10-12
Start date
2010-09-01
Completion date
Unknown
Last updated
2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

healthy male adults

Interventions

Injection of [11C]racropride and [11C]FLB457 intravenously for PET scan before and after administration of aripirazole. The dosage of aripiprazole is 6mg.

Sponsors

Molecular Imaging Center, National Institute of Radiological Sciences
Lead Sponsor

Eligibility

Sex/Gender
Male

Inclusion criteria

Inclusion criteria: Healthy male subjects who have the ability to provide informed consent

Exclusion criteria

Exclusion criteria: -Psychiatric disorders including drug dependence -Serious medical illness

Design outcomes

Primary

MeasureTime frame
Regional difference of D2 receptor occupancy by aripiprazole using [11C]raclopride and [11C]FLB457.—

Countries

Japan

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026